阿利西尤单抗治疗对急性心肌梗死患者PCI术后MACE风险的影响  

Effect of Alirocumab Treatment on the Risk of MACE in Patients with Acute Myocardial Infarction after PCI

作　　者：陈颖 王海珠[1] CHEN Ying;WANG Hai-zhu(In-patient Area(Ⅱ)of Cardiovascular Internal Medicine,Zhoukou Central Hospital,Zhoukou 466000,Henan Province,China)

机构地区：[1]周口市中心医院心血管内科二病区,河南周口466000

出　　处：《罕少疾病杂志》2025年第4期69-71,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的分析阿利西尤单抗治疗对急性心肌梗死(AMI)患者经皮冠状动脉介入术(PCI)术后主要心血管不良事件(MACE)风险的影响。方法选取本院2023年1月至2024年1月收治的102例行PCI术治疗的AMI患者,并采用随机数字表法分组,接受瑞舒伐他汀治疗的对照组(51例)和阿利西尤单抗联合瑞舒伐他汀治疗的观察组(51例),比较两组患者血脂水平、炎症因子以及MACE发生情况。结果治疗后,观察组总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平[(3.19±0.52)mmol/L、(1.88±0.38)mmol/L、(1.39±0.34)mmol/L]均低于对照组[(3.77±0.58)mmol/L、(2.33±0.51)mmol/L、(1.91±0.48)mmol/L](P<0.05);观察组超敏C反应蛋白、白细胞介素6水平[(1.21±0.28)mg/L、(12.40±3.22)ng/L]显著低于对照组[(1.40±0.31)mg/L、(16.65±3.49)ng/L](P<0.05);随访6个月,观察组MACE发生率显著低于对照组(P<0.05)。结论AMI患者PCI术后采用阿利西尤单抗治疗效果确切,对患者血脂、炎症反应及MACE发生率均具有改善作用。Objective The impact of alirocumab treatment on the risk of major adverse cardiovascular events(MACE)in patients who have undergone percutaneous coronary intervention(PCI)following acute myocardial infarction(AMI)is analyzed.Methods A total of 102 patients with AMI who underwent PCI in the hospital from January 2023 to January 2024 were selected,and divided into the control group(51 cases,rosuvastatin treatment)and the observation group(51 cases,combined treatment with alirocumab and rosuvastatin)using the random number table method.Blood lipid levels,inflammatory factors,and the incidence of MACE were compared between groups.Results After treatment,the levels of total cholesterol,triacylglycerol,low-density lipoprotein cholesterol,high-sensitivity C-reactive protein and interleukin-6 were significantly lower in the observation group[(3.19±0.52)mmol/L,(1.88±0.38)mmol/L,(1.39±0.34)mmol/L,(1.21±0.28)mg/L and(12.40±3.22)ng/L]than in the control group[(3.77±0.58)mmol/L,(2.33±0.51)mmol/L,(1.91±0.48)mmol/L,(1.40±0.31)mg/L and(16.65±3.49)ng/L](P<0.05).Six months of follow-up found that the incidence of MACE was significantly lower in the observation group(P<0.05).Conclusion Alirocumab is effective in the treatment of AMI patients after PCI,which can improve blood lipids,inflammatory response and reduce the incidence of MACE.

关 键 词：急性心肌梗死 经皮冠状动脉介入术 阿利西尤单抗 心血管不良事件 

分 类 号：R542.22[医药卫生—心血管疾病]